Member Info for inanaco

Its was a Joke Ruck ........... calm down

and of course the Mab itself can kill ..

Scancell has overcome this limitation and produced a series of high affinity mAbs targeting glycans that are highly over-expressed on cancer cells, and which directly lyse tumour cells without the need for the complement system or immune effector cells. This is a form of immunogenic cell death (ICD) and has the potential to initiate an anti-tumour immune response following the secretion of damage-associated molecular patterns (DAMPs), leading to long-term tumour control

The Mab (scancells and AZN) migrates into the cell .. then destroys the cell from the inside

azn Mab target is

TROP2 expression in NSCLC
Immunohistochemical studies in 100 AdC samples revealed no expression (total score 0) in 53 (53.0%), weak expression (total score 1-4) in 24 (24.0%), moderate expression (total score 6 and 8) in 14 (14.0%), and strong expression (total score 9 and 12) in nine (9.0%). Thus, according to the aforementioned criteria, TROP2 was overexpressed in 23 (23.0%) of the AdC cases (Figure 3). In the 64 SCC cases, seven (10.9%) showed a lack of expression, 16 (40.6%) showed weak expression, 15 (23.4%) showed moderate expression, and 26 (32.9%) showed strong expression. TROP2 overexpression was noted in 41 (64.1%) of the SCC cases (Figure 3). TROP2 overexpression was significantly more frequent in SCC (P < 0.01) (Table 3).

so those weak expression patients may get extra benefit from a High Avidity Mab ..

the efficacy comes from Binding .. like super Glue

Mabs for viral neutralise ... they don't need to Kill .. the virus is dead in effect until it infects a cell

Well the stuff i posted yesterday on the method of action of AZN $6 billion Mab should raise your eyebrows, indeed those with hair loss should now have distinct growth emanating from the fore head ... AZN target in lung cancer is probably about 30/40 % of patients ... so these $ numbers are Huge in comparison ..

AvidMab .... looks very appetizing and the fact that it could "upgrade" AZN MAB to allow binding to the weaker targets on NSLC is significant

I think once this is in the clinic and ""Avidity"" is proven ... expect many deals to follow ..

Yes echo that to ATB ... Violindog

now over lay that with the science Map ........... and you can see just how wrong the market Trend was ...
and you for that matter even with Diggles giving you hints ...

the "bear market" in you could not let go ... its cost YOU ... the rest of us have been buying in the lows not moaning that it was not low enough ...

if Not ............

Next Knowlesi post on Funding

Post expected August 2022
subject Discounted Dilution
Estimated SP £8 ...
Estimated discount to market 5%
Knowlesi new buy target £7 ...

Good luck Knowlesi

Knowlesi ... check your broker .. you might get some at 5.5p ...

look under heading "Scancell" corporate Action .. you should have one after the bazooka buy

so the next point to look at is Expression of Trop2 .... the Target for the $6 billion Mab ....

TROP2 expression in NSCLC
Immunohistochemical studies in 100 AdC samples revealed no expression (total score 0) in 53 (53.0%), weak expression (total score 1-4) in 24 (24.0%), moderate expression (total score 6 and 8) in 14 (14.0%), and strong expression (total score 9 and 12) in nine (9.0%). Thus, according to the aforementioned criteria, TROP2 was overexpressed in 23 (23.0%) of the AdC cases (Figure 3). In the 64 SCC cases, seven (10.9%) showed a lack of expression, 16 (40.6%) showed weak expression, 15 (23.4%) showed moderate expression, and 26 (32.9%) showed strong expression. TROP2 overexpression was noted in 41 (64.1%) of the SCC cases (Figure 3). TROP2 overexpression was significantly more frequent in SCC (P < 0.01) (Table 3).

Ch in negotiation with Big Pharma ...

https://www.123rf.com/photo_56952940_little-businessman-sign-with-giant-pen-at-office.html

Start with Rucks £5 billion Mcap ................ correction Error

personally i think its down to Desk size Crumbs ...

To View ...... Big Pharma you need "wide Screens"

... sorry ... AZN new Mab is not approved ... it's further ahead than Scancell ... however i don't think AZN are buying in to it "with a warranty" or maybe you know something different ..

anyway enough .. all this crap about you have to be Big to be successful is absolute rubbish .. proof of that is "Dyson"

depends which one gives me a cheaper deal ... the warranty is with BMW

that is why the spread is so tight ........

and £5 billion ? Mcap

what has that got to do with it ......... ? do you buy a car based on the balance sheet of BMW ?